vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v12i1.567vsp-378Research ArticleОБМЕН ОПЫТОМEXCHANGE OF EXPERIENCEЦИКЛЕСОНИД В ЛЕЧЕНИИ БРОНХИАЛЬНОЙ АСТМЫ У ДЕТЕЙCICLESONIDE IN TREATMENT OF CHILDHOOD BRONCHIAL ASTHMAЭфендиеваК. Е.EfendievaK. E.kamilla@nczd.ruНамазова-БарановаЛ. С.Namazova-BaranovaL. S.namazova@nczd.ruЛевинаЮ. Г.LevinaYu. G.kamilla@nczd.ruВишнёваЕ. А.VishnevaE. A.kamilla@nczd.ruАлексееваА. А.AlekseevaA. A.kamilla@nczd.ruБокучаваЕ. Г.BokuchavaE. G.kamilla@nczd.ruНаучный центр здоровья детей РАМН, Москва; Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияScientific Centre of Children Health, Moscow; I.M. Sechenov First State Medical University,Russian FederationНаучный центр здоровья детей РАМН, Москва; Первый Московский государственный медицинский университет им. И.М. Сеченова; Российский национальный исследовательский медицинский университет им. Н.И. Пирогова, МоскваРоссияScientific Centre of Children Health, Moscow; I.M. Sechenov First State Medical University; The Russian National Research Medical University named after N.I. Pirogov, Moscow,Russian FederationНаучный центр здоровья детей РАМН, Москва; Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияScientific Centre of Children Health, Moscow; I.M. Sechenov First State Medical UniversityRussian FederationНаучный центр здоровья детей РАМН, МоскваРоссияScientific Centre of Children Health, Moscow,Russian FederationНаучный центр здоровья детей РАМН, Москва; Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияScientific Centre of Children Health, Moscow; I.M. Sechenov First State Medical UniversityRussian FederationНаучный центр здоровья детей РАМН, МоскваРоссияScientific Centre of Children Health, MoscowRussian Federation201303022013121Вопросы современной педиатрии117122Copyright © Эфендиева К.Е., Намазова-Баранова Л.С., Левина Ю.Г., Вишнёва Е.А., Алексеева А.А., Бокучава Е.Г., 20132013Эфендиева К.Е., Намазова-Баранова Л.С., Левина Ю.Г., Вишнёва Е.А., Алексеева А.А., Бокучава Е.Г.Efendieva K.E., Namazova-Baranova L.S., Levina Y.G., Vishneva E.A., Alekseeva A.A., Bokuchava E.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/378

В статье представлен обзор клинических исследований, свидетельствующих о высокой эффективности и безопасности применения нового ингаляционного глюкокортикоида на основе циклесонида в лечении бронхиальной астмы у детей. Циклесонид — экстрамелкодисперсный глюкокортикоид, имеющий высокую легочную биодоступность (52%), из которых 55% распределяется в периферических дыхательных путях, играющих важную роль в развитии и течении астмы. Высокая противовоспалительная активность, минимальное число системных и местных побочных эффектов, однократный прием в сутки делают использование данного препарата предпочтительным в педиатрической практике.

The review of clinical trials, confirming high efficacy and safety of new inhalation glucocorticoid based on ciclesonide in treatment of childhood bronchial asthma is shown in this article. Ciclesonide is an extra-fine dispersed glucocorticoid with high pulmonary bioavailability (52%), 55% of it is distributed through peripheral respiratory tract, which plays significant role in development and clinical course of asthma. High anti-inflammatory activity, minimal systemic and local side effects and one-time administration per day make this drug usage preferable in pediatric practice.

 

бронхиальная астмадетиингаляционные глюкокортикоидыэффективностьбезопасностьциклесонид:bronchial asthmachildreninhalation glucocorticoidsefficacysafetyciclesonideReferencesReport Global Strategy for Asthma Management and Prevention. GINA. 2011.//www.ginasthma.org.Report Global Strategy for Asthma Management and Prevention. GINA. 2011.//www.ginasthma.org.Namazova-Baranova L. S. Allergiya u detei: ot teorii — k praktike. [Allergy in children: from theory to practice]. Chapter VIII. Moscow. 2010–2011. Pp. 268–474.Namazova-Baranova L. S. Allergiya u detei: ot teorii — k praktike. [Allergy in children: from theory to practice]. Chapter VIII. Moscow. 2010–2011. Pp. 268–474.Efendiyeva K. E. Influence of different methods of treatment on a quality of life in children with bronchial asthma. Author’s abstract of doctoral thesis. Moscow. 2005. 107 pp.Efendiyeva K. E. Influence of different methods of treatment on a quality of life in children with bronchial asthma. Author’s abstract of doctoral thesis. Moscow. 2005. 107 pp.Halterman J. S., Yoos H. L., Conn K. M. et al. The impact of childhood asthma on parental quality of life. J. Asthma. 2004; 41: 645–653.Halterman J. S., Yoos H. L., Conn K. M. et al. The impact of childhood asthma on parental quality of life. J. Asthma. 2004; 41: 645–653.Baranov A. A., Khaitov R. M. Allergology and immunology. Clinical recommendations for pediatricians. Moscow. 2011. Pp. 123–124.Baranov A. A., Khaitov R. M. Allergology and immunology. Clinical recommendations for pediatricians. Moscow. 2011. Pp. 123–124.Brand P. L., Carroll W., Wildhaber J. H. Parent and child perceptions on the impact of asthma: global results from the «Room to Breathe» survey. Eur. Respir. Society electronic abstract book. 2009; 785: abs 4438.Brand P. L., Carroll W., Wildhaber J. H. Parent and child perceptions on the impact of asthma: global results from the «Room to Breathe» survey. Eur. Respir. Society electronic abstract book. 2009; 785: abs 4438.Barnes P. J., Pedersen S., Busse W. W. Efficacy and safety of inhaled corticosteroids. Am. J. Respir. Crit. Care Med. 1998; 157: 51–53.Barnes P. J., Pedersen S., Busse W. W. Efficacy and safety of inhaled corticosteroids. Am. J. Respir. Crit. Care Med. 1998; 157: 51–53.Derendorf H. Pharmacokinetic and pharmacodinamic properties of inhaled corticosteroids in relation to efficacy and safery. Respir. Med. 1997; 91 (Suppl. A): 22–28.Derendorf H. Pharmacokinetic and pharmacodinamic properties of inhaled corticosteroids in relation to efficacy and safery. Respir. Med. 1997; 91 (Suppl. A): 22–28.Dietzel K., Engelstatter R., Keller A. Ciclesonide: an on-siteactivated steroid. Prog. Respir. Res. 2001; 31:91–93.Dietzel K., Engelstatter R., Keller A. Ciclesonide: an on-siteactivated steroid. Prog. Respir. Res. 2001; 31:91–93.Hubner M., Hochhaus G., Derendorf H. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol. Allergy Clin. North Am. 2005; 25: 469–488.Hubner M., Hochhaus G., Derendorf H. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol. Allergy Clin. North Am. 2005; 25: 469–488.Derendorf H., Nave R., Drollmann A., Cerasol F., Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur. Respir. J. 2006; 28: 1042–1050.Derendorf H., Nave R., Drollmann A., Cerasol F., Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur. Respir. J. 2006; 28: 1042–1050.Nave R., Meyer W., Fuhst R., Zech K. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm. Pharmacol. Ther. 2005; 18 (6): 390–396.Nave R., Meyer W., Fuhst R., Zech K. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm. Pharmacol. Ther. 2005; 18 (6): 390–396.Allen D. B. Growth supression by glucocorticoid therapy. Endocrinol. Metabol. Clin. North. Am. 1996 (25): 699–717.Allen D. B. Growth supression by glucocorticoid therapy. Endocrinol. Metabol. Clin. North. Am. 1996 (25): 699–717.Levina Yu. G. Clinical-immunological efficacy and safety of combined drugs in treatment of bronchial asthma in children. Author’s abstract of doctoral thesis. Moscow. 2005. 143 pp.Levina Yu. G. Clinical-immunological efficacy and safety of combined drugs in treatment of bronchial asthma in children. Author’s abstract of doctoral thesis. Moscow. 2005. 143 pp.Bisgaard H. Delivery of inhaled medication to children. J. Asthma. 1997; 34: 443–467.Bisgaard H. Delivery of inhaled medication to children. J. Asthma. 1997; 34: 443–467.Lindstroem M. Particles in small airways: mechanisms for deposition and clearance. Thesis, Stockholm: Karolinska Institute. 2004. 52 p.Lindstroem M. Particles in small airways: mechanisms for deposition and clearance. Thesis, Stockholm: Karolinska Institute. 2004. 52 p.Schuepp K. G., Jauernig J., Janssens H. M. et al. In vitro determination of the optimal particle size for nebulised aerosol delivery to infants. J. Aerosol. Med. 2005; 18 (2): 225–235.Schuepp K. G., Jauernig J., Janssens H. M. et al. In vitro determination of the optimal particle size for nebulised aerosol delivery to infants. J. Aerosol. Med. 2005; 18 (2): 225–235.Nenasheva N. M. Ciclesonide (Alvesko) — a new inhalation corticosteroid for treatment of bronchial asthma. Effective pharmacotherapy. 2012; 2: pp. 3–14.Nenasheva N. M. Ciclesonide (Alvesko) — a new inhalation corticosteroid for treatment of bronchial asthma. Effective pharmacotherapy. 2012; 2: pp. 3–14.Torrego Fernandez A., Munoz Cano R. M. Clinical relevance of distal airway involvement in asthma. Arch. Bronconeumol. 2011; 47 (Suppl. 2): 17–19.Torrego Fernandez A., Munoz Cano R. M. Clinical relevance of distal airway involvement in asthma. Arch. Bronconeumol. 2011; 47 (Suppl. 2): 17–19.van den Berge M., Ten Hacken N. H., van der Wiel E., Postma D. S. Treatment of the bronchial tree from beginning to end: targeting small airway inflammation in asthma. Allergy. 2013; 68 (1): 16–26.van den Berge M., Ten Hacken N. H., van der Wiel E., Postma D. S. Treatment of the bronchial tree from beginning to end: targeting small airway inflammation in asthma. Allergy. 2013; 68 (1): 16–26.Gelfand E. W., Georgitis J. W., Noonan M., Ruff M. E. Once-daily ciclesonide in children: efficacy and safety in asthma. J. Pediatr. 2006; 148: 377–383.Gelfand E. W., Georgitis J. W., Noonan M., Ruff M. E. Once-daily ciclesonide in children: efficacy and safety in asthma. J. Pediatr. 2006; 148: 377–383.Pedersen S., Potter P., Dachev S., Bosheva M., Kaczmarek J., Springer E., Dunkel J., Engelstatter R. Respir. Med. 2010; 104: 1618–1628.Pedersen S., Potter P., Dachev S., Bosheva M., Kaczmarek J., Springer E., Dunkel J., Engelstatter R. Respir. Med. 2010; 104: 1618–1628.von Berg A., Engelstatter R., Minic P., Sreckovic M., Gar cia M. L. G., Latos T., Vermeulen J. H., Leichtl S., Hellbardt S., Bethke T. D. Com parison of the efficacy and safety of ciclesonide 160 μg once daily vs. budesonide 400 μg once daily in children with asthma. Pediatr. Allergy Immunol. 2007; 18: 391–400.von Berg A., Engelstatter R., Minic P., Sreckovic M., Gar cia M. L. G., Latos T., Vermeulen J. H., Leichtl S., Hellbardt S., Bethke T. D. Com parison of the efficacy and safety of ciclesonide 160 μg once daily vs. budesonide 400 μg once daily in children with asthma. Pediatr. Allergy Immunol. 2007; 18: 391–400.Skoner D. P., Maspero J., Banerji D. and Ciclesonide Pediatric Growth Study Group. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics. 2008; 121: 1–14.Skoner D. P., Maspero J., Banerji D. and Ciclesonide Pediatric Growth Study Group. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics. 2008; 121: 1–14.

The authors declare that there are no conflicts of interest present.